EXEL Reports STELLAR-303 Results
Exelixis reports final STELLAR-303 analysis showing non-significant OS trend favoring zanzalintinib and Tecentriq combo in non-liver metastases mCRC
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Exelixis reports final STELLAR-303 analysis showing non-significant OS trend favoring zanzalintinib and Tecentriq combo in non-liver metastases mCRC